The identification of the repeat expansion which causes Huntington's disease in 1993 soon led to a clinical genetic test for the condition, enabling people at risk to have a test to determine whether they will get the disease. The primary determinant of age at onset in Huntington's disease is CAG repeat length, but in recent years there have been advances in identifying and characterising genetic modifiers which influence age at onset. This has led to the question of whether these data may be applied clinically to improve clinical practice. Here, on behalf of the European Huntington’s Disease Network (EHDN) Genetic Testing and EHDN Genetic Modifiers Working Groups, we review the current state of genetic testing for Huntington's disease and consider the personal impact that pre-symptomatic genetic testing has on those that undertake it. We then discuss how genetic information could be used to improve onset prediction clinically, and whether it could be applied in clinical trials stratification. We conclude by proposing short, medium and long-term recommendations to improve the use of genetic data to in clinical practice and clinical trials.
RawlinsM. Huntington's disease out of the closet?Lancet2010; 376: 1372–1373.
2.
RawlinsMDWexlerNSWexlerAR, et al.The prevalence of Huntington's disease. Neuroepidemiology2016; 46: 144–153.
3.
FisherERHaydenMR. Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Mov Disord2014; 29: 105–114.
4.
LangbehnDRBrinkmanRRFalushD, et al.A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet2004; 65: 267–277.
5.
BrinkmanRRMezeiMMTheilmannJ, et al.The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet1997; 60: 1202–1210.
6.
DuyaoMAmbroseCMyersR, et al.Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet1993; 4: 387–392.
7.
WexlerNSLorimerJPorterJ, et al.Venezuelan Kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A2004; 101: 3498–3503.
8.
GeM-HD-Consortium. Identification of genetic factors that modify clinical onset of Huntington's disease. Cell2015; 162: 516–526.
9.
Hensman MossDJPardiñasAFLangbehnD, et al.Identification of genetic variants associated with Huntington’s disease progression: a genome-wide association study. Lancet Neurol2017; 16: 701–711.
10.
GeM-HD-Consortium. CAG Repeat not polyglutamine length determines timing of Huntington's disease onset. Cell2019; 178: 887–900.e14.
11.
LeeJMHuangYOrthM, et al.Genetic modifiers of Huntington disease differentially influence motor and cognitive domains. Am J Hum Genet2022; 109: 885–899.
12.
CiosiMMaxwellACummingSA, et al.A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes. EBioMedicine2019; 48: 568–580.
13.
WrightGEBCollinsJAKayC, et al.Length of uninterrupted CAG, independent of polyglutamine size, results in increased somatic instability, hastening onset of Huntington disease. Am J Hum Genet2019; 104: 1116–1126.
14.
McAllisterBDonaldsonJBindaCS, et al.Exome sequencing of individuals with Huntington's disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset. Nat Neurosci2022; 25: 446–457.
15.
BaigSSStrongMRosserE, et al.22 Years of predictive testing for Huntington's disease: the experience of the UK Huntington's Prediction Consortium. Eur J Hum Genet2016; 24: 1396–1402.
16.
MacLeodRTibbenAFrontaliM, et al.Recommendations for the predictive genetic test in Huntington's disease. Clin Genet2013; 83: 221–231.
17.
Van RijMCDe RademaekerMMoutouC, et al.Preimplantation genetic diagnosis (PGD) for Huntington's disease: the experience of three European centres. Eur J Hum Genet2012; 20: 368–375.
18.
LeeJMRamosEMLeeJH, et al.CAG Repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology2012; 78: 690–695.
19.
UK Office for National Statistics. Annual mid year population estimates. In: ONS, editor. UK. 2018.
20.
LosekootMvan BelzenMJSenecaS, et al.EMQN/CMGS best practice guidelines for the molecular genetic testing of Huntington disease. Eur J Hum Genet2013; 21: 480–486.
21.
PotterNTSpectorEBPriorTW. Technical standards and guidelines for Huntington disease testing. Genet Med2004; 6: 61–65.
22.
BeanLBayrak-ToydemirP. American College of Medical Genetics and Genomics Standards and Guidelines for Clinical Genetics Laboratories, 2014 edition: technical standards and guidelines for Huntington disease. Genet Med2014; 16: e2.
23.
AllittoBAMcClatcheyAIBarnesG, et al.Assay by polymerase chain reaction (PCR) of multi-allele polymorphisms in the Huntington's disease region of chromosome 4. Mol Cell Probes1992; 6: 513–520.
24.
ValdesJMTagleDAElmerLW, et al.A simple non-radioactive method for diagnosis of Huntington's disease. Hum Mol Genet1993; 2: 633–634.
25.
RiessONoerremoelleASoerensenSA, et al.Improved PCR conditions for the stretch of (CAG)n repeats causing Huntington's disease. Hum Mol Genet1993; 2: 637.
26.
WarnerJPBarronLHBrockDJ. A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. Mol Cell Probes1993; 7: 235–239.
27.
Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell1993; 72: 971–983.
28.
WarnerJPBarronLHGoudieD, et al.A general method for the detection of large CAG repeat expansions by fluorescent PCR. J Med Genet1996; 33: 1022–1026.
29.
AndrewSEGoldbergYPTheilmannJ, et al.A CCG repeat polymorphism adjacent to the CAG repeat in the Huntington disease gene: implications for diagnostic accuracy and predictive testing. Hum Mol Genet1994; 3: 65–67.
30.
IbañezKPolkeJHagelstromRT, et al.Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study. Lancet Neurol2022; 21: 234–245.
31.
OrthMHandleyOJSchwenkeC, et al.Observing Huntington's disease: the European Huntington's disease network's REGISTRY. PLoS Curr2010; 2: RRN1184.
32.
QuarrellOWHandleyOO'DonovanK, et al.Discrepancies in reporting the CAG repeat lengths for Huntington's disease. Eur J Hum Genet2012; 20: 20–26.
33.
McDonnellEIWangYGoldmanJ, et al.Age of onset of Huntington's disease in carriers of reduced penetrance alleles. Mov Disord2021; 36: 2958–2961.
34.
IbañezKJadhavBZanovelloM, et al.Increased frequency of repeat expansion mutations across different populations. Nat Med2024; 30: 3357–3368.
35.
SemakaAKayCDotyC, et al.CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease. J Med Genet2013; 50: 696–703.
36.
BrocklebankDGayanJAndresenJM, et al.Repeat instability in the 27-39 CAG range of the HD gene in the Venezuelan kindreds: counseling implications. Am J Med Genet B Neuropsychiatr Genet2009; 150B: 425–429.
37.
SemakaACollinsJAHaydenMR. Unstable familial transmissions of Huntington disease alleles with 27-35 CAG repeats (intermediate alleles). Am J Med Genet B Neuropsychiatr Genet2010; 153b: 314–320.
38.
SemakaAKayCBelfroidRD, et al.A new mutation for Huntington disease following maternal transmission of an intermediate allele. Eur J Med Genet2015; 58: 28–30.
39.
WheelerVCPersichettiFMcNeilSM, et al.Factors associated with HD CAG repeat instability in Huntington disease. J Med Genet2007; 44: 695–701.
40.
LeeJMChaoMJHaroldD, et al.A modifier of Huntington's disease onset at the MLH1 locus. Hum Mol Genet2017; 26: 3859–3867.
41.
CiosiMCummingSAChatziA, et al.Approaches to sequence the HTT CAG repeat expansion and quantify repeat length variation. J Huntingtons Dis2021; 10: 53–74.
42.
WrightGEBBlackHFCollinsJA, et al.Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies. Lancet Neurol2020; 19: 930–939.
43.
DawsonJKayCBlackHF, et al.The frequency and clinical impact of synonymous HTT loss-of-interruption and duplication-of-interruption variants in a diverse HD cohort. Genet Med2024; 26: 101239.
44.
GoldbergYPMcMurrayCTZeisierJ, et al.Increased instability of intermediate alleles in families with sporadic Huntington disease compared to similar sized intermediate alleles in the general population. Hum Mol Genet1995; 4: 1911–1918.
45.
GelleraCMeoniCCastellottiB, et al.Errors in Huntington disease diagnostic test caused by trinucleotide deletion in the IT15 gene [1]. Am J Hum Genet1996; 59: 475–477.
46.
MargolisRLStineOCCallahanC, et al.Two novel single–base-pair substitutions adjacent to the CAG repeat in the Huntington Disease Gene (IT15): implications for diagnostic testing. Am J Hum Genet1999; 64: 323–325.
47.
PêcheuxCMouretJFDürrA, et al.Sequence analysis of the CCG polymorphic region adjacent to the CAG triplet repeat of the HD gene in normal and HD chromosomes. J Med Genet1995; 32: 399–400.
48.
DawsonJBaine-SavanhuFKCiosiM, et al.A probable cis-acting genetic modifier of Huntington disease frequent in individuals with African ancestry. HGG Adv2022; 3: 100130.
49.
Genetic Modifiers of Huntington's Disease Consortium, LeeJMMcLeanZL, et al.Genetic modifiers of somatic expansion and clinical phenotypes in Huntington's disease reveal shared and tissue-specific effects. bioRxiv. 2024.
50.
GeM-HDLeeJ-MMcLeanZL, et al.Genetic modifiers of somatic expansion and clinical phenotypes in Huntington’s disease highlight shared and tissue-specific effects. Nat Genet2025; 57: 1426–1436.
51.
Findlay BlackHKayCDawsonJ, et al.Ascertainment of uninterrupted CAG repeat length and disease-modifying variants in fragment-based genetic testing for Huntington disease. Genet Med Open2024; 2: 101882.
52.
GymrekMWillemsTReichD, et al.Interpreting short tandem repeat variations in humans using mutational constraint. Nat Genet2017; 49: 1495–1501.
53.
TaylorASBarrosDGobetN, et al.Repeat detector: versatile sizing of expanded tandem repeats and identification of interrupted alleles from targeted DNA sequencing. NAR Genom Bioinform2022; 4: lqac089.
54.
ClarksonCChenZRoccaC, et al.A population-wide exploration of the CAG repeat size and structure in the 100,000 genomes project and UK Biobank. Mov Disord2024; 40: 561–566.
55.
CiosiMCummingSAlshammariA, et al.Library preparation and MiSeq sequencing for the genotyping-by-sequencing of the Huntington disease HTT exon one trinucleotide repeat and the quantification of somatic mosaicism. Research Square. 2018.
56.
FlowerMLomeikaiteVCiosiM, et al.MSH3 Modifies somatic instability and disease severity in Huntington’s and myotonic dystrophy type 1. Brain2019; 142: 1876–1886.
57.
SwamiMHendricksAEGillisT, et al.Somatic expansion of the Huntington's disease CAG repeat in the brain is associated with an earlier age of disease onset. Hum Mol Genet2009; 18: 3039–3047.
58.
MavaddatNMichailidouKDennisJ, et al.Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet2019; 104: 21–34.
59.
PanagiotisBArielleRMAndersK, et al.Integrating a Polygenic Risk Score into a clinical setting would impact risk predictions in familial breast cancer. J Med Genet2023; 61: 1426–1436.
60.
LeeAMavaddatNWilcoxAN, et al.BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med2019; 21: 1708–1718.
61.
ArcherSBabb de VilliersCScheiblF, et al.Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: a multi-methods study. PLoS One2020; 15: e0229999.
62.
CarverTHartleySLeeA, et al.Canrisk Tool-A web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants. Cancer Epidemiol Biomarkers Prev2021; 30: 469–473.
63.
PhulkaJSAshrafMBajwaBK, et al.Current state and future of polygenic risk scores in cardiometabolic disease: a scoping review. Circ Genom Precis Med2023; 16: 286–313.
64.
NaderianMHamedMEVaseemAA, et al.Effect of disclosing a polygenic risk score for coronary heart disease on adverse cardiovascular events: 10-year follow-up of the MI-GENES randomized clinical trial. medRxiv. 2024.
65.
LeonenkoGBakerEStevenson-HoareJ, et al.Identifying individuals with high risk of Alzheimer’s disease using polygenic risk scores. Nat Commun2021; 12: 4506.
66.
DingYHouKBurchKS, et al.Large uncertainty in individual polygenic risk score estimation impacts PRS-based risk stratification. Nat Genet2022; 54: 30–39.
67.
EllisNTeeAMcAllisterB, et al.Genetic risk underlying psychiatric and cognitive symptoms in Huntington's disease. Biol Psychiatry2020; 87: 857–865.
FahedACPhilippakisAAKheraAV. The potential of polygenic scores to improve cost and efficiency of clinical trials. Nat Commun2022; 13: 2922.
70.
DamaskAStegPGSchwartzGG, et al.Patients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from alirocumab treatment in the ODYSSEY OUTCOMES trial. Circulation2020; 141: 624–636.
PihlstrømLMorsetKRGrimstadE, et al.A cumulative genetic risk score predicts progression in Parkinson's disease. Mov Disord2016; 31: 487–490.
73.
LeonardHBlauwendraatCKrohnL, et al.Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson's disease. J Med Genet2020; 57: 331–338.
74.
ScahillRIFaragMMurphyMJ, et al.Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington’s disease decades before clinical motor diagnosis. Nat Med2025; 31: 807–818.
